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Abstract 
Objective In systemic sclerosis (SSc) a persistent tissue repair process leads to progressive fibrosis 
of the skin and internal organs.  The role of mesenchymal stem cells (MSCs), which 
characteristically initiate and regulate tissue repair, has not been fully evaluated.  We sought to 
investigate whether dividing metakaryotic MSCs are present in SSc skin, and test whether 
exposure to the disease microenvironment activates MSCs leading to transdifferentation.  
Methods Skin biopsy material from recent onset diffuse SSc patients was examined by 
collagenase spread of 1mm thick surface-parallel sections, in order to identify metakarytoic 
dividing stem cells in each tissue plane.  Adipose-derived MSCs from healthy controls were 
treated with dermal blister fluid from diffuse SSc patients, and profiled by next generation 
sequencing, or evaluated for phenotypic changes relevant to SSc.  Differential responses of 
dermal fibroblasts were studied in parallel.   Results MSC-like cells undergoing active 
metakaryotic division were identified in SSc but not control sections, most prominent in the deep 
dermis and adjacent to damaged microvessels, in both involved and clinically uninvolved skin.  
Furthermore, exposure to SSc blister fluid caused selective MSC activation, inducing a 
myofibroblast signature, whilst reducing signatures of vascular repair and adipogenesis and 
enhancing migration and contractility.  Microenvironment factors implicated in inducing 
transdifferentiation include the pro-fibrotic growth factor TGFβ, presence of lactate and 
mechanosensing, whereas the microenvironment Th2 cytokine IL-31, enhanced osteogenic 
commitment (calcinosis).  Conclusion Dividing MSC-like cells are present in the SSc disease 
microenvironment where multiple factors, likely acting in concert, promote transdifferentiation, 







In scleroderma (systemic sclerosis, SSc), a prototypic disease for understanding fibrosis, 
infiltration of the affected tissues by dysregulated immune cells at the disease onset is followed 
by a persistent tissue repair process resulting in progressive fibrosis of the skin and internal 
organs (1).  Within the early disease microenvironment cross-talk between immune cells and 
tissue resident cells is presumed responsible for promoting myofibroblast activation, leading to 
increased extracellular matrix (ECM) production, and progression to scarring and fibrosis of the 
skin and internal organs (2).  However, the exact mechanisms and cellular interactions involved, 
as well as the cellular origin of the activated myofibroblasts, are not fully understood, limiting 
the development of specific therapeutic approaches. Unlike other fibrotic disorders, in SSc the 
early disease microenvironment can be readily sampled using a minimally invasive technique to 
obtain lesional tissue fluid, allowing for the identification of candidate factors and modelling of 
the interaction with target cells (3).  
Mesenchymal stem cells (MSCs) are tissue resident cells with multi-lineage potential which are 
involved in organogenesis but quiescent in healthy adult tissue (4, 5).  However, following 
wounding or tissue damage MSCs become activated, divide and orchestrate tissue repair (6).  
MSCs are implicated as having a role in fibrosis, since their activation can account for the 
excessive tissue remodeling seen (7).  The role of MSCs in SSc has not been fully explored, but 
their involvement in SSc could account for several disease manifestations, most prominently the 
fibrosis, but also dysregulated vascular repair and ectopic bone formation (calcinosis)(8, 9).  
Furthermore, depletion of MSCs through multiple cycles of activation and division in SSc tissues 
could explain tissue atrophy, loss of subcutaneous fat and non-healing wounds seen in late stage 
disease (10).  
In this study, we investigate local activation of MSCs in SSc skin lesions, using a novel histologic 
method to detect metakaryotic dividing cells (11).  Furthermore, we use treatment of cultured 
adipose derived MSCs with SSc lesional tissue fluid, combined with next generation sequencing 
(NGS), to comprehensively model the interaction between the early disease microenvironment 
and MSCs and go on to investigate the role of individual candidate factors present in the disease 
tissue.  
Patients and Methods 
Patient samples 
All patients had a definite diagnosis of SSc according to the 2013 ACR/EULAR SSc classification 
criteria (12).  All human studies were carried out in compliance with the declaration of Helsinki. 
SSc patients from the diffuse cutaneous subset within the first 2 years of disease, were selected 
for blister fluid (BF) sampling. Using a dermal suction apparatus (Electronic Diversities, MD, USA) 
and a technique originally devised by Sondergaard et al, an 8mm blister was formed on the 
anterior forearm of patients and healthy controls under negative pressure (280-310 mmHg) over 
3 hours(13). The interstitial fluid in the blister was aspirated using a 23-gauge needle. 100-250 µl 
of fluid is collected per blister and stored in 1.5 ml Eppendorf tubes following centrifugation at 
4°C for 10 minutes and decantation of the supernatant. Samples were kept in 20 µl aliquots at -
80°C until needed, and then used in tissue culture diluted 1 in 125 in DMEM with 0.2%FCS. The 
L-lactate Colorimetric Assay (Biovision, CA, USA) was used to detect the amount of lactate in SSc 
and healthy control BF,  IL-31 was assayed by ELISA (R&D systems, #DY2824), and TGFβ by ELISA 
(R&D Systems, Quantikine ELISA #DB100B).  
Skin biopsy collection and metakaryotic staining 
Skin punch biopsies of 4mm diameter and 5mm depth were taken from the involved anterior 
forearm skin of 4 patients with recent onset diffuse SSc less than 2 years since the first non-
Raynauds symptoms, and 4 healthy controls, after written informed consent (using a study 
specific consent form and patient information sheet).  In further replicate studies, 4 further 
recent onset diffuse SSc patients were studied by biopsy of involved forearm skin and clinically 
uninvolved skin from the back. Biopsies were fixed in Carnoys fixative (3 parts ethanol to 1-part 
glacial acetic acid), mixed immediately before adding the tissue. The biopsies were stored at 4°C 
with fixative being replaced three times, once every hour, before being stored long term in 70% 
ethanol at 4°C. Using a method developed by Dr Elena Gostjeva(14), tissues were assessed for 
the presence of metakaryotic stem cells. Biopsies were cut laterally into three 1 mm sections 
using a scalpel and each piece digested in collagenase II (0.8mg/ml) at 37°C for two hours. 
Sections were then placed in 1M HCL at 60°C for 8 minutes for hydrolysis to occur. Acid treatment 
releases the aldehydes by cleavage of the N bases and formation of aldehyde groups to which 
Schiff’s staining binds. Schiff’s staining is DNA specific and staining intensity is proportional to 
DNA concentration (15).  After hydrolysis, sections were rinsed in distilled H2O and placed into a 
Petri dish at room temperature containing 45% acetic acid for 15-30 minutes. Individual sections 
were placed on glass microscope slides and 5µl acetic acid pipetted on top before covering with 
a glass coverslip and spreading the section with slight pressure until a thin uniform layer was 
achieved. Slides were placed on dry ice until frozen, before immersion in Schiff’s reagent for one 
hour, and then rinsed twice in 2 x saline-sodium citrate (SSC) buffer, once for 30 seconds, once 
quickly. Slides were then rinsed with distilled H20 and dipped in 1% Giemsa solution for 5 minutes 
before rinsing in Sorensen buffer and distilled H2O. Slides were allowed to dry fully before being 
immersed in xylene for 3 hours and mounting with DPX mountant.  Slides were scanned with a 
LEICA SCN400F scanner. Quantification of metakaryotic nuclei was conducted by counting the 
number of bell-shaped nuclei in 10 randomly selected 20x magnification field views per slide and 
determining the average number of MSCs per section. 
Culturing cells 
Human adipose-derived MSCs, isolated from liposuction fat, were obtained commercially 
(Adipose-Derived Mesenchymal Stem Cells; Normal, Human (ATCC, #PCS-500-011). These cells 
have been demonstrated to be multipotent, capable of differentiating down the adipogenic, 
osteogenic and chondrogenic lineages, and shown by FACS to be positive for CD29, CD44, CD73, 
CD90, CD105 and CD166, and negative for CD14, CD19, CD34 and CD45(16). DMEM 
supplemented with 20% serum and penicillin/streptomycin, was used to culture MSCs for three 
days in plastic T75 flasks (Corning; New York, USA), before replacing media with 10% serum. 
Negative controls were represented by DMEM supplemented with 0.2% serum. Where specified, 
MSCs were cultured in osteogenic (OIM) or adipogenic induction media (AM)(Gibco, UK) in N=4 
replicates per experiment. Cells were trypsinised and passaged by incubation with Trypsin/EDTA 
(Life Technologies, Paisley, UK). 
Primary cultures of normal skin fibroblasts were obtained from 4mm punch biopsies sampled 
from forearm skin of healthy controls. Biopsy material was minced and cultured in 20% serum.  
Cultures were inspected daily by light microscopy and when a fibroblast outgrowth was detected, 
cells were washed with DPBS and contaminating epithelial cells were detached by Trypsin/EDTA. 
Fibroblasts were cultured further and then subcultured in T75 tissue culture flasks.  Passaged 
cells were cultured further in DMEM supplemented with 10% FCS and penicillin/streptomycin 
solution, incubated at 37°C 5% CO2 in T75 flasks. All fibroblasts were used at passage 3-5 for each 
experiments to correspond with MSC passage numbers and to avoid the effects of senescence.  
Protein and qPCR assays 
Cells were lysed in RIPA buffer then separated by SDS PAGE, and transferred to nitrocellulose 
blots which were probed with the following primary antibodies; CTGF (Santa Cruz, #sc14939), 
Collagen I (Abcam, #ab34710), αSMA (Sigma, #a2547) and GAPDH (abcam, #ab8245), and then 
species specific secondary labelled antibodies developed with ECL.  For qPCR analysis, RNA was 
extracted from lysed MSCs using Quiagen RNAeasy kit, and qPCR performed with the following 
primers TBP (used as reference gene) forward 5’-AGTGACCCAGCATCACTGTTT-3’, reverse 5’-
GGCAAACCAGAAACCCTTGC-3’, CTGF forward 5’-GACCTGGAAGAGAACATTAAGAAGG-3’,reverse 
5’-TGAGTATGTCTTCATGCTGGTG -3’, COL1A2 forward 5’-TGCTTGCAGTAACCTTATGCCTA-3’, 
reverse 5’-CAGCAAAGTTCCCACCGAGA-3’, αSMA forward 5’-CCGACCGAATGCAGAAGGA-3’, 
reverse 5’-ACAGAGTATTTGCGCTCCGAA-3’. 
Next generation sequencing 
Analysis was conducted using 43 base paired end strands measuring 15 million reads per sample. 
The study was separated into two groups, one using healthy control dermal fibroblasts, and the 
other, adipose-derived MSCs, in order to compare the patterns of gene expression in SSc 
environment activated MSCs with those induced in fibroblasts. The RNAseq analyses was 
conducted in collaboration with UCL Genomics.  
A heatmap was constructed using R software, based on the expression of 20 candidate genes, 
chosen for their potential relevance to SSc pathology, MSC differentiation capabilities or ability 
to induce pro-fibrotic factors.  Pathway analysis was performed using Ingenuity Pathway Analysis 
(IPA) software to highlight predicted pathways involved, in the context of their physiological 
significance. This software uses the differentially expressed genes from the RNAseq data, 
inputted as FASTQ files, and with its own database called Knowledge Base, predicts the pathways 
activated or deactivation, networks of molecules involved and biological function by gene 
ontology. These predictions are based on existing literature and experimental data. For the 
purpose of this study, only significantly changed RNA molecules were analysed where p<0.05. 
IPA analysis compares two FASTQ files, and in this study, two comparisons were made; 0.2% 
media vs SSc blister fluid treated MSCs and, SSc blister fluid vs healthy control blister fluid treated 
MSCs. Significance was calculated by the software as –Log (p-value), and as such, all values above 
1.3 were significant, indicating p<0.05. Z-scores are computed by the software representing the 
level of matching between the predicted relationship direction (activation/deactivation) and the 
observed gene expression. A Z-score of >2 or <-2 is calculated as significant matching.  
Comparison was made with the results of Gene Ontology biologic process analysis in order to 
validate the IPA (http://geneontology.org/). 
Furthermore, the software was used to predict networks of focus molecules, implicated in the 
responses of MSCs to SSc blister fluid. A score was algorithmically computed for each network 
based on the number of nodes, their significance and directionality. The score indicates the 
likelihood of connected nodes being generated by chance. A score of above 2 means that there 
is less than 1 in 100 chance of this. Nodes are either green or red, with green indicating activated 
by SSc blister fluid, and red, deactivation by blister fluid. The intensity of the colour of each node 
is a representation of the Z-score, i.e. the directionality of the connection, and how significant it 
is. Uncoloured, grey nodes are of molecules that were not found to be differentially expressed in 
the original RNAseq dataset and have been filled in by the software to complete the network. 
The shapes of the nodes represent the predicted function of that gene including enzymes, 
protein, receptors, kinases, cytokines, growth factors and transcription factors.  
Modelling stiff and soft ECM in the microenvironment 
ECM stiffness was modelled in vitro by culturing cells on Softwell collagen coated hydrogels of 
specific stiffness (Cell Guidance Systems SW12-COL-50, SW12-COL-4). 4 kPa and 50 KPa gels were 
used to model healthy and SSc skin, respectively. MSCs were seeded at a density of 1 x 105 cells 
per well in N=4 replicate experiments, and incubated in DMEM supplemented with 10% serum, 
with media being changed every 3-4 days, being careful not to disrupt the hydrogel layer.  
Study approval 
Written informed consent was obtained from all patients and healthy controls under ethical 
committee approval, in compliance with the Helsinki Declaration.  Ethical committee approval 
was obtained under “NHS Health Research Authority, NRES Committee London-Hampstead, HRA, 
reference number 6398- “Elucidating the pathogenesis of scleroderma”.  
Results  
Presence of metakaryotic dividing MSC-like cells in scleroderma lesional tissue 
Biopsies from the involved forearm skin of patients with recent onset severe diffuse cutaneous 
subset SSc and from matched sites in healthy controls (HC)(both n=4) were evaluated for the 
presence of metakaryotic divisions, using 1mm sections cut parallel to the skin surface.  
Quantification of the number of metakaryotic nuclei in each section was conducted in ten 
randomly chosen 20x magnification field views per section per biopsy.  In the initial screen no 
metakaryotic nuclei were detected in any of the healthy control sections. In contrast, up to four 
metakaryotic nuclei were detected in any one 20x magnification field view of the middle and 
lower sections of SSc biopsies (Figure 1A). Only one metakaryotic cell was detected in the top 
section of all the SSc sections examined. Middle and lower SSc biopsy sections contained 
significantly more metakaryotic nuclei than the control samples (p<0.0001) and slightly more 
metakaryotic nuclei were detected in the deepest section than the middle section (upper HC 0, 
SSc 0.05±0.05, middle HC 0, SSc 1.225±0.06 p<0.0001, lower HC 0, SSc 1.45±0.16 p<0.0001 
(mean±SEM)). A range of metakaryotic nuclear forms were seen in the deep SSc sections, 
including bell forms, pipe shaped forms, and cup shaped forms, in association with thick collagen 
fibrils (Figure 1B).  
Furthermore, vascular abnormalities were frequently seen in SSc where microvascular cells 
containing multiple small cyst-like  structures were observed, possibly reflecting apoptotic blebs, 
and consistent with the known microvascular damage seen in this disease(8).  Metakaryotic cells 
were found adjacent to these abnormal microvessels in the deep dermis of SSc tissues (Figure 
1C). Summary images from each patient sample are shown in Supplementary data Figure S1.  
In a further confirmatory analysis (n=4 diffuse SSc patients) samples from involved forearm skin 
and clinically uninvolved tissue from the back were compared.  As before, frequent metakaryotic 
forms were seen in the deeper layer fibrotic tissue in association with collagen fibrils.  Even in 
the clinically uninvolved skin, metakaryotic forms were seen in the deep layer fibrotic tissue, and 
adjacent to abnormal >30µm microvessels which were frequently observed in both involved and 
clinically uninvolved skin(Table 1).  Smaller healthy-looking microvessels (20-30µm) in association 
with metakaryotic cells were seen in both involved and clinically uninvolved tissue, possibly 
indicating de novo angiogenesis(Figure 1D).  
 
Characteristics Affected Unaffected Control Comments 
Metakaryotic stem cell 
fraction in mesenchymal,  
fibrotic sections of the skin. 
3±1 x 10
-3 3±1 x 10-3  1 x 10-4 The thickness of fibrotic parts is two-
three times higher in affected skin 
biopsies compared to unaffected 
counterparts.  
Metakaryotic stem cell 
fraction in epithelial  sections 
of the skin. 
2±1 x 10
-5 2±1 x 10-5 1 x 10-5 
 
Diseased, damaged blood 
vessels (> 30 um diameter). 
Yes Yes No ~90% of blood vessels in affected 
skin, 
~70% of blood vessels in unaffected 
skin look damaged  or dying (Fig. 2). 
Small (20-30 um diameter) 
normal blood vessels with 
visible stem cells. 
Yes Yes Rare Possible ‘de novo’ angiogenesis, 
attempt to regenerate dead blood 
vessels. 
Table 1 Analysis of metakaryotic cell frequency in involved and clinically uninvolved SSc skin 
biopsy material.  Metakarytoic divisions were seen in both lesional forearm and non-lesional 
clinically uninvolved tissue from the back.  Metakarytoic divisions were seen within fibrotic tissue 
in deeper layers, and adjacent to microvasculature.  
 
Additional cytological abnormalities were also seen in the fibrotic material including many bi-
nucleated cells with morphologic features indicating the presence of osteoclasts, as well as 
calcified material (Figure 1E).  Osteoclasts, which are derived from macrophages under the 
influence of myostatin/RANKL(17), are not known to be present normally in the skin and were 
not found in any of the healthy control sections examined.  
Modelling the interaction between SSc disease microenvironment and MSCs.  
In view of the presence of dividing MSC-like cells in the SSc skin, an attempt was made to model 
and understand how their activation was being initiated within the disease microenvironment.  
Human MSCs, derived from subcutaneous fat of healthy controls (16, 18), were maintained in 
tissue culture with blister fluid (BF) sampled from the forearm skin lesions of patients with recent 
onset severe diffuse subset SSc, as well as BF from healthy controls (both n=4) diluted 1:125 in 
0.2% DMEM.   Our recent analysis has implicated the IL-6 family Th2 cytokine IL-31 as having a 
role in SSc skin and lung fibrosis.  IL-31 is secreted by Th2 cells and the receptor IL-31RA/OSMR 
expressed by tissue resident cells including MSCs.  Furthermore, in our analysis IL-31 is present 
in the dermal blister fluid, at higher levels than other disease-associated cytokines.  Therefore, 
the addition of recombinant IL-31 was used to study the potential effects of a disease 
microenvironment cytokine. MSCs or normal human dermal fibroblasts (n=4 replicates) were 
maintained in tissue culture with SSc or healthy control blister fluid (BF), or with IL-31 (50ng/ml), 
in order to model the effect of the disease microenvironments on resident tissue cells.  After 16 
hours the cells were lysed for RNA extraction and analysed by Illumina RNAseq technology to 
profile the patterns of gene expression induced by the SSc BF.  
Hierarchical clustering of samples indicated complete separation of MSCs from healthy dermal 
fibroblasts, indicating that the two cells types have distinct expression profiles regardless of 
treatment (Figure 2A). Since MSCs are not lineage committed cells, it is expected that they would 
have an expression profile reflecting their stem-cell pluripotency, while healthy dermal 
fibroblasts are an established differentiated cell line which express genes related to their function 
in the skin. Consistent with this NT5E, Thy1 and Eng were expressed under basal conditions by 
MSCs.  
Of the candidate genes studied, the largest change in gene expression in the BF treated MSCs 
was the induction of 3 genes, CEMIP, IL6 and ACAN, highly relevant to SSc pathogenesis, and 
consistent with induction of an invasive tissue repair phenotype in MSCs, not seen in the treated 
fibroblasts, where the expression of these genes was low.  ACAN encodes the proteoglycan 
aggrecan, previously shown to be strongly elevated in SSc skin fibroblast cultures (19).  Also, the 
expression of ACTA2, a myofibroblast-associated gene encoding -SMA, was higher in SSc BF 
treated MSCs, compared to healthy control BF treated MSCs.  CTGF and COL1A1 were also more 
highly expressed in SSc BF treated MSCs (Figure 2B). Taken together, these findings indicate 
myofibroblast commitment of the cells exposed to SSc microenvironment.  
NT5E which encodes CD73, is a gene relating to the pluripotency of MSCs. SSc blister fluid 
treatment led to reduced NT5E in MSCs indicating commitment to differentiation. It is possible 
that under SSc blister fluid conditions, MSCs, even as soon as 16 hours after treatment, begin to 
lose some MSC characteristics and differentiate. Furthermore, physiologically, MSCs express 
vascular growth factors as part of their role in endothelial and vascular homeostasis. Expression 
of VEGFC was significantly decreased by SSc blister fluid (Figure 2B). Furthermore, GAS1, a cell 
cycle arrest gene, was suppressed by SSc BF treatment, consistent with induction of a 
proliferative phenotype.  However, notably, there was no difference between the treatments 
with respect to TGF or TGFR gene expression by MSCs.  While a reduction in THY1 expression 
has been shown to be indicative of MSC differentiation, the expression of this gene was not 
affected by the SSc microenvironment treatment. Likewise, fibronectin FN1 was not upregulated 
by any of the treatments. 
Unlike the findings with MSCs, dermal fibroblasts were less consistently responsive to the specific 
BF treatments. While some replicate samples clustered together, others clustered with samples 
from other treatments and did not share the same expression profile (Figure 2A). ALCAM, COL4A1 
and ENG were downregulated in fibroblasts, as were CEMIP, IL6 and ACAN, unlike the induction 
of these genes seen in MSCs. However, notably, -SMA expression was higher in SSc BF treated 
fibroblasts than control media treated fibroblasts. IL-31, as an SSc microenvironment cytokine, 
had more of an effect on dermal fibroblasts than on MSCs and induced elevated expression of 
CXCL5, ANXA1 and IL-33 involved in angiogenesis, cell adhesion and inflammation respectively.  
 IL-31 was present at a high level in the BF trending to higher levels in SSc  (HC N=15 samples, 
range 0-21, median 0, SSc N=28, range 0-1117, median 0 pg/ml, P=NS), (Figure 2C), However, in 
terms of NGS signature IL-31 generally failed to recapitulate the effects of adding SSc BF to the 
MSCs (Figure 2A&B).  
Based on the above findings, it was concluded that SSc microenvironment exposure consistently 
induces a myofibroblast-like commitment of MSCs, and that the effects on differentiated 
fibroblasts were less marked and non-consistent.    
Ingenuity Pathway Analysis of SSc microenvironment treatments 
In addition, Ingenuity Pathway Analysis (IPA) was used to predict signaling pathways and network 
effects involved in the MSC activation. IPA pathway analysis illustrated the complexity of gene 
expression in response to SSc microenvironments and implicated both known SSc-related 
pathways and novel generated disease associated pathways in the MSC activation. Overall, many 
pro-fibrotic pathways of relevance to complex fibrotic pathology were predicted by the analysis 
software (Figure2D).  The most significantly activated pathway in response to SSc blister fluid was 
the integrin linked kinase pathway (ILK) (Z-score of -2.52982 with 21.9% overlap between the 
predicted genes involved and the observed genes)(Figure 2D). Some of the genes in the ILK 
pathway include ACTA2 and integrins. The ILK gene is involved with β1 and β3 integrin-mediated 
signal transduction, and is associated with multiple cellular functions including cell migration, 
proliferation, and adhesion (20).  Interestingly, aside from this pathway, integrin signaling was 
found to be reduced by the IPA, supporting the idea that downstream signaling through ILK was 
the dominant integrin-dependent response.  
Furthermore, IL-8, NRF2 and VEGF signaling were predicted to be reduced by the IPA results. The 
VEGF pathway decreased in response to SSc blister fluid with 21.4% of the known genes of this 
pathway found differentially expressed in the RNAseq dataset.  
Pathways involved in cell migration were upregulated by SSc blister fluid. Both actin cytoskeleton 
remodelling and Rho based motility are pathways found to be significantly involved in MSCs 
treated with SSc blister fluid. -SMA was implicated to be involved in both processes. Moreover, 
MSC differentiation is regulated via RhoA, which in turn is increased by SSc blister fluid. RhoA has 
influence on cell shape, signalling and cytoskeletal integrity. Signalling via ROCK, RhoA 
determines cell shape drives stem cell commitment.  
Supportive of MSC differentiation in SSc microenvironments, the NANOG pathway, which is 
associated with pluripotency of mammalian cells, was significantly deactivated.    
Ingenuity Pathway Analysis: networks of responsive genes 
Aside from predicting individual pathways involved in the response of MSCs to SSc blister fluid, 
the software created networks of focus molecules linked together based on biological 
connectivity. Two significant networks were identified by the software when comparing 
expression of media control and SSc blister fluid treated MSCs (Shown as Supplementary data 
Figure S3). One is a network predicted to be involved in connective tissue and organismal injury, 
and cell morphology, with a high score of 37, consisting of 33 focus nodes. It is centralised around 
the growth factor ERBB2(Figure S3A). Other factors of relevance to the finding of SSc blister fluid 
induced cell migration are Rho GTPases, also highlighted in this network. Furthermore, 
osteogenic differentiation associated genes fit into this network, such as TWIST2. The second 
predicted network was focused around connective tissue growth and development (Figure S3B). 
This pathway is centered around the CTGF gene, and, together with Col1A1, it is clear that SSc 
blister fluid induces MSC expression of genes highly associated with SSc fibrosis and 
myofibroblast activation. MMPs are also part of this network, supporting an effect on migration 
and tissue remodeling.  
Ingenuity Pathway Analysis: predicted upstream regulators 
IPA has the useful ability of predicting upstream regulators that explain the differential 
expression observed in the RNAseq data. The software uses Knowledge base database to predict 
biological processes being activated or deactivated by certain molecules and their effects on 
downstream molecules. P-values calculated by this analysis identify how well the RNAseq 
measured genes are regulated by a specific regulator and is calculated using Fisher’s Exact Test 
where significance is p<0.01.  Using this approach, TGF was predicted to be an upstream 
regulator of over 100 of the differentially expressed genes analysed. These include ACTA2, ACAN, 
collagen genes, Rho GTPases, TWIST genes, NT5E, IL6 and TGFR, where p=8.62x10-30 and Z=-
0.372.  
Furthermore, of relevance to the female predominance of SSc, the oestrogen receptor was 
predicted to be a significant upstream regulator of SSc blister fluid induced pathways. A Z-score 
of 2.534 indicated significant activation and a p-value of 2.46x10-8 showing a high level of overlap 
between observed and theoretical pathway activation.  The oestrogen receptor was also a 
predicted to be a significant upstream regulator for ANXA1, CTGF, collagen molecules, NT5E and 
MMPs. P=9.95x10-15 for this regulation and Z=-1.769.  
IPA analysis: biologic significance 
Described in Table 2, are the predicted biological functions which differed between treatment 
conditions. Functions consistently activated by SSc blister fluid when compared to DMEM 
control, include differentiation and proliferation of multilineage progenitor cells, fibrosis and 
wound healing, supporting the notion that SSc blister fluid induces MSCs to differentiate into pro-
fibrotic wound healing cells. Furthermore, the functions found to be deactivated by SSc blister 
fluid included functions regarding the development and growth of vasculature, such as the 
formation of new blood vessels. Fitting these pathways into biological significance shows that 
most of the involved functions that differ between the two conditions relate to vasculogenesis 
and angiogenesis. This is a significant finding and may be relevant to the failure to repair the 
microvasculature in SSc. 
 
Categories Diseases or Functions 
Annotation 
p-Value Z-Score Molecules 
Cell Death and Survival apoptosis 2.44E-39 -0.103 381 
Cellular Assembly and Organization, Cellular 
Function and Maintenance 
organization of 
cytoplasm  
1.49E-27 -0.921 234 
Tissue Development  growth of epithelial 
tissue  
3.15E-22 -0.757 119 
Cellular Assembly and Organization, Tissue 
Development  
fibrogenesis 1.34E-22 -0.42 77 
Organismal Injury and Abnormalities  wound  6.22E-16 -0.204 49 
Cellular Movement, Connective Tissue 
Development and Function 
cell movement of 
fibroblast cell lines  
1.69E-15 -0.495 48 
Cellular Assembly and Organization, Cellular 
Function and Maintenance, Tissue 
Development  
formation of actin 
stress fibres  
7.15E-15 -1.193 50 
Cardiovascular System Development and 
Function, Cellular Movement 
migration of vascular 
endothelial cells  
2.42E-14 -1.335 39 




3.51E-14 0.217 53 
Connective Tissue Development and 
Function, Tissue Morphology 
quantity of connective 
tissue cells 
1.23E-11 -1.309 48 
Cellular Movement  cellular infiltration  2.65E-10 -1.103 68 
Cell-To-Cell Signalling and Interaction, Cellular 
Assembly and Organization, Cellular Function 
and Maintenance 
formation of focal 
adhesions  
1.24E-13 -1.53 35 
Organismal Development  growth of vessel  1.81E-11 1.871 32 




1.59E-09 0.069 43 




4.23E-09 0.719 24 
Cardiovascular System Development and 
Function   
vascularization  5.99E-12 0.383 46 
 
Table 2 Ingenuity pathway analysis (IPA) indicated that SSc BF when compared to DMEM media 
alone, had induced multiple pathways (no shading)  including apoptosis of cells, epithelial 
growth, fibrogenesis, wound repair, cell movement, osteoblast differentiation and infiltration, 
as well as down regulation (shaded grey) of vasculogenesis, adipogenesis, and chondrogenesis, 
when compared to controls treated with media only. 
 
 
Although the healthy control BF induced some of the changes seen with SSc BF, but lesser in 
magnitude (Figure 2A&B), significant differences were demonstrated between the two 
treatments (Table 3). Compared to healthy control BF, SSc BF induced cell differentiation, 
proliferation of multilineage progenitor cells, wound healing, fibrosis and necrosis, whereas 
endothelial cell proliferation, vessel formation, angiogenesis and vasculogenesis were decreased 
(Table 3).  
 
Categories Diseases or 
Functions 
Annotation  
p-Value Z-Score Molecules 
Cellular Development differentiation of 
cells  
5.89E-13 3.169 81 





1.28E-07 0.838 9 
Organismal Injury and Abnormalities, Tissue 
Morphology  
healing of wound  2.22E-07 1.254 13 
Organismal Injury and Abnormalities  fibrosis  1.03E-08 0.092 29 
Cell Death and Survival  necrosis  5.62E-14 0.57 93 
Cellular Growth and Proliferation  cell proliferation of 
vascular endothelial 
cells  
6.47E-07 -0.633 11 
Embryonic Development, Organismal 
Development  
development of 
body axis  
7.16E-07 -0.373 40 
Organismal Development  formation of vessel 7.25E-07 -0.786 11 
Cell-To-Cell Signalling and Interaction, 
Hematological System 
activation of blood 
cells  
7.27E-07 -2.047 27 
Hematological System Development and 
Function, Tissue Morphology  
quantity of blood 
cells  
7.54E-07 -1.756 39 
Cardiovascular System Development and 
Function, Organismal Development  
angiogenesis  1.53E-16 -2.465 52 
Cardiovascular System Development and 
Function, Organismal Development  
vasculogenesis 1.88E-15 -2.615 45 
Cardiovascular System Development and 
Function   
development of 
vasculature  
1.83E-14 -2.464 53 
Table 3 Comparison was made between SSc BF treated and control BF treated MSCs, revealing 
pathways induced by SSc (no shading) or decreased by SSc vs control (shaded grey).  
Significantly altered pathways induced by SSc included proliferation of progenitor cells, wound 
healing, fibrosis and necrosis, whereas pathways relating to endothelial cell proliferation, body 
axis development and angiogenesis were inhibited by the SSc BF treatment.  
 
Comparison was made with the results of Gene Ontology biologic process analysis, which in 
general confirmed enhanced fibrogenesis, collagen synthesis, connective tissue repair, as well as 
dysregulated angiogenesis and vascular repair (Supplementary data Tables S1 and S2). Overlap 
with the IPA included differentiation of osteoblasts, formation of focal adhesions, actin filament 
formation (enhanced by SSc BF), as well as cardiovascular development and morphogenesis 
(reduced).    
Phenotypic changes induced in MSCs by scleroderma blister fluid 
Because of the above findings we went on to attempt to validate phenotype changes implicated 
in the NGS, by modelling using MSCs maintained in tissue culture.  The induction of αSMA, 
indicating myofibroblast differentiation pattern, was investigated further by qPCR.  A significant 
difference between αSMA expression induced by SSc blister fluid compared with healthy control 
blister fluid was observed even when diluted 1:125 in DMEM (HC blister fluid treated 3.9±0.5, 
SSc blister fluid treated MSCs 8.4±1.6, p=0.048 mean±SEM, expression relative to basal) (Figure 
3A).  Furthermore, since TGFβ had been implicated as an extracellular driver of the NGS changes, 
its potential role was investigated further. SSc blister fluid diluted 1:125 induced αSMA 
expression equivalent to addition of TGFβ (4ng/ml) (media control 16.8±1.2, SSc blister fluid 
treated 29.4±1.1, p<0.0004, TGFβ treated 32.7±1.8, p<0.004, relative expression), and the 
stimulatory effect of SSc BF was antagonised by the TGFβ1-3 inhibitory antibody 1D11 (mean 
10.3±0.4, p<0.0001) supporting a central role for TGFβ in the SSc BF effects (Figure 3B).  Also, 
further BF samples taken from healthy controls and  SSc patients were assayed to confirm the 
presence of TGFβ, which trended to higher levels in the patient samples (TGFβ HC range 78-667, 
mean 288, SSc  136-696, mean 328pg/ml P=NS) ( Figure 3C).  In addition, inhibitors of PI3K 
signalling (Wortmannin), and the ERK inhibitor (U0126) blocked the αSMA induction by SSc BF, 
implicating these signalling pathways (p<0.0001 for each inhibitor vs SSc BF treated).  Based on 
these experiments it was concluded that in monolayer culture, induction of αSMA in MSCs by SSc 
blister fluid is dependent on TGFβ plus signalling via PI3K and ERK.  
Scratch wound migration was used as a measure of invasiveness/spreading of activated MSCs in 
the SSc microenvironment (Figure 3D).  Compared to medium control, SSc BF induced MSC 
scratch migration (residual scratch area at 24 hours, control 1.33±0.09, SSc BF treated 0.72±0.11 
mean±SEM mm2, p<0.016) equivalent to 10% serum positive control.  IL-31 appeared to enhance 
migration of MSCs (but P NS),  inhibited by Wortmanin implicating PI3K.   
Furthermore, the SSc BF induced collagen gel contraction by the MSCs, consistent with a 
differentiation into contractile myofibroblast-like cells (residual gel mass in media control 
0.11±0.008 g, SSc blister fluid treated 0.066±0.009, mean±SEM g, p=0.002) (Figure 3E).  
Since loss of adipose tissue is associated with severe skin involvement in SSc, the effects of SSc 
BF were explored in an MSC adipogenesis assay, indicating partial inhibition of the adipogenic 
commitment by the SSc BF (trending but P NS) and consistent with the pathway analysis (Figure 
3F). 
Furthermore, protein assays for αSMA, collagen I and the matricellular protein CTGF (each N=3 
replicates) were used to validate the myofibroblast-like transdifferentiation of MSCs.  SSc BF 
induced these protein factors, more than control BF and consistent with some kind of pro-
fibrotic transdifferentation of the MSCs.  The changes were fully antagonised by addition of 
SB431542  (10uM), a small molecule inhibitor of Alk4,5&7(21) (Figure 3G&H).  
Role of mechanosensing in SSc microenvironment 
Since the ILK and RhoA pathways had been implicated in the IPA analysis, and because increased 
stiffness (mechanical stress) in affected tissues is a hallmark feature of SSc (22), it was 
hypothesised that mechanosensing might be an important factor in determining the activation 
of MSCs within the disease microenvironment.  We measured the effect of altered substrate ECM 
and also tested the effect of adding the mechanosensing inhibitor of MRTF-A signalling CCG-
1423(23) on the induction of MSCs.  4kPa and 50kPa Softwell gel culture matrices were used to 
model soft healthy control skin and stiff scleroderma skin matrices respectively in N=4 replicate 
experiments. αSMA could not be effectively induced on the soft matrices by either SSc BF 
treatment or by TGFβ, but could be fully induced on 50kPa gels (on 50kPa gels, control 1.85±0.49, 
TGFβ treated 99.5±41, p<0.007, on 4kPa control 2.55±1.8, TGFβ treated 1.93±1.7, pNS relative 
expression) (Figure 4A&B).  By contrast, CTGF, an early response matricellular protein, could be 
induced on both soft and stiff gels (on 50kPa control 19.8±6.03, TGFβ treated 598±85.1, p<0.029, 
on 4kPa control 18.3±6.96, TGFβ treated 465±349, pNS, relative expression).  Both αSMA and 
CTGF were suppressed fully by CCG-1423 (αSMA in TGFβ+CCG-1423 treated, 0.59±0.20 p<0.0061, 
CTGF in TGFβ+CCG-1423 treated, 1.67±1.09 p<0.045) consistent with dependence on MRTF-A 
signaling and mechanosensing (Figure 4A&B).   
Also, since ectopic bone formation (calcinosis) is a significant problem for SSc patients, occurring 
at sites of pressure or enhanced mechanical stress, an attempt was made to model the 
osteogenic differentiation of MSCs on soft or stiff gels.  Osteogenic differentiation could not be 
effectively induced on the soft 4 kPa gels, but was induced by both TGFβ and IL-31 on 50kPa gels 
(on 4kPa gels, control 0.33±0.33, TGFβ treated 0.667±0.33, IL-31 treated 0±0),CCG-1423 treated 
0±0, on 50kPa gels control1.67±0.33, TGFβ treated 3±0, IL-31 treated 3.33±0.33, CCG-1423 
treated 0.33±0.33, Aluzarin red assay (0-4))(Figure 4C).   
It was concluded that mechanical stress in the disease microenvironment is likely a determinant 
of the potential activation of MSCs, including their commitment to myofibroblast or else 
osteoblast dependent on the context, and that growth factors and cytokines were capable of 
inducing osteogenic differentiation in these cells, dependent on a stiff extracellular matrix.  
Effect of lactate in blister fluid on MSC myofibroblast commitment 
Furthermore, since there is failure of angiogenesis, plus the presence of microvascular damage 
and ischaemia in SSc, lactate as a product of glycolytic metabolism is a potential factor acting 
within the SSc disease microenvironment.  Lactate is transported into and out of mitochondria 
via a lactate-protein co-transporter which is inhibited by α-cyano-4-hydroxycinnamic acid 
(αCHCA)(24). Accordingly, MSCs in monolayer culture were treated with SSc or control BF with 
or without αCHCA and then assayed by qPCR for αSMA.  These experiments indicated that as 
expected SSc BF induced αSMA, but dependent on the presence of lactate (Figure S2A).  The 
lactate inhibitor suppressed αSMA levels to near zero and below basal levels supporting the idea 
that presence of lactate is a required factor for myofibroblast commitment (control αSMA 
43.9±5.9, SSc BF treated 57.3±4.4, SSc BF+ αCHCA treated 15.5±4.6 p<0.015).  
SSc and control BF samples were assayed for the presence of lactate, showing lactate present in 
the 10-60mM range and trending to higher levels in the disease (control BF range 8-36, mean 24 
SSc BF range 14-62, mean 48mmol/l, P=NS) (Figure S2B). Furthermore, as shown in Figure S2C, 
SSc BF, but not control BF, induced gel contraction similar to positive control with 10% serum 
(DMEM control 0.13±0.026, SSc blister fluid 0.08±0.007, healthy control blister fluid 0.16±0.002, 
residual gel mass at 24hrs in g, p=0.023). Lactate treatment of MSCs failed to significantly alter 
gel contraction (lactate treated 0.108±0.019 g, p=NS). Furthermore, addition of the lactate 
inhibitor did not significantly alter SSc BF induced gel contraction (Figure S2C). It was concluded 
that lactate transport into mitochondria is a required factor for αSMA induction, but not required 
for SSc BF induced contractility in MSCs.  
 
Discussion 
This is the first study to demonstrate the presence of metakaryotic cell divisions, believed to 
represent dividing MSCs, in SSc skin, in association with thick collagen fibrils in the deeper layers 
of the dermis and adjacent to damaged microvessels in both involved and clinically unaffected 
skin.  Such metakaryotic divisions were recently described as being characteristic of dividing 
tissue resident stem cells, seen during organogenesis and then recapitulated during wound 
healing or in pathologic tissue remodeling, such as cancer or atherosclerosis (14). The findings 
support the idea that MSCs are being activated and dividing in the SSc tissues at an early stage of 
disease development, and are consistent with current concepts regarding the role of these cells 
in fibrosis (7, 25).  In general, previous work has demonstrated that the deeper dermis is the 
predominant site of αSMA expressing cells, where myofibroblast activation appears maximal in 
this disease.  
Furthermore, our findings support the idea that adipose derived MSCs are becoming activated 
through exposure to the early disease microenvironment, differentiating towards damaging pro-
fibrotic cells, and away from potentially beneficial reparative effects such a vascular repair, 
cartilage repair and maintenance of subcutaneous fat.  These findings confirm previous studies 
indicating that MSCs can commit to become tissue resident myofibroblast-like cells, 
demonstrated by lineage tracing in multiple mouse models of fibrotic disease (26-32).  Most 
notably, Varga and colleagues have demonstrated in the bleomycin mouse model, that 
subcutaneous fat derived stem cells transdifferentate to myofibroblasts present in the deep 
dermal layer of the fibrotic lesions (32). Furthermore, previous studies have demonstrated MSC-
like cells (pericytes) as migrating from perivascular sites in SSc tissue and showing intermediary 
stage cells consistent with myofibroblast trans-differentiation (33).  Moreover, gene expression 
profiling indicates that MSCs exposed to the SSc microenvironment undergo multiple phenotype 
changes consistent with migration/invasion, wound healing, connective tissue development and 
enhanced osteogenic commitment, as well as loss of adipogenesis.  These changes could account 
for the chronic and excessive tissue repair seen as well as the loss of subcutaneous adipose cells 
seen both in SSc and wounds (32).   
However, counter to the proposal that MSCs have a damaging profibrotic role in SSc, are previous 
findings that these cells may have restorative anti-inflammatory and immunosuppressive effects 
likely to be of benefit in autoimmune disorders.  For example, umbilical cord derived MSCs have 
been shown to attenuate inflammation and fibrosis in a mouse model of SSc lung fibrosis (34).  It 
may be that any beneficial therapeutic effects would best be utilized in the late stage disease, 
such as in  autologous fat transplantation used as a regenerative therapy in late atrophic phase 
SSc (35).  
Pathway analysis predicted that TGFβ as well as estrogen receptor agonists were important 
upstream inducers of the changes seen in MSCs exposed to SSc microenvironment, consistent 
with current models of fibrosis indicating an essential role for TGFβ and also supporting a role for 
estradiol in driving SSc fibrosis (36, 37).  Inhibition of TGFβ abolished the myofibroblast 
transdifferentation of MSCs indicating that it might be driving the MSC commitment.  However, 
mechanosensing and the presence of lactate were also demonstrated as being required factors 
present in the microenvironment.   
The osteogenic commitment seen is also highly relevant to the calcinosis seen in SSc, which is a 
severely disabling manifestation of the disease(9).   In general, such ectopic bone tissue formation 
is seen at sites of trauma and mechanical stress and as shown here depends on mechanosensing 
(38). IL-31, an IL-6 family member cytokine, present at high levels in the tissue fluid, might 
contribute to the enhanced migration and osteogenic differentiation, but only partially 
accounted for the full spectrum of changes seen in MSC activation. 
Although the exact cellular origin of myofibroblasts in dermal fibrotic lesions is not exactly 
known, it is likely that there are multiple contributing sources such as tissue resident fibroblasts, 
circulating monocyte like cells (fibrocytes)(39), as well as cells transitioning  through an EMT-like 
process(40), or through EndoMT(41), as well as perivascular stem cells (33). Our study indicates 
that subcutaneous adipose MSCs are a further potential source of the pathogenic myofibroblasts.  
In mice lineage tracing experiments have indicated that a specific subset of MSCs (Lck+ Sca-) are 
responsible for maintaining the deep dermal and subdermal tissues and that these cells are 
responsible for the overproduction of extracellular matrix in the early stages of wound healing 
(42).  It is possible that the human equivalent cells are involved in driving SSc pathogenesis, 
accounting for the fibrosis which is predominantly affecting the deep dermis, and is associated 
with loss of subcutaneous adipose tissues. 
There are certain limitations of this study, including the relatively small number of skin and tissue 
fluid samples analysed, and the use of healthy donor adipose MSCs rather than lesional MSCs in 
the tissue culture experiments. However, taken together, the overall picture that emerges is of 
multiple factors in the disease microenvironment inducing adipose MSC commitment to 
pathogenic myofibroblasts.  These effects on MSCs seem to be more specific than the effects on 
differentiated dermal fibroblasts. Several inhibitory treatments were assessed, including anti-
TGFβ antagonists, as well as pathway signaling inhibitors, and lactate response antagonists, each 
of which suppressed the MSC to myofibroblast differentiation.  Such antagonists, if they could 
safely be used, could arrest the development of this and other fibrotic diseases. 
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Figure 1 Metakaryotic stem cells in affected, unaffected SSc  and normal skin biopsies.  (A) Skin 
biopsies from the involved forearm skin of diffuse cutaneous SSc patients, and of matched sites 
in healthy controls, were assessed for the presence of metakaryotic cells applying ~ 1x1 mm thick 
biopsy tissue parts (in ‘A’) spreading and Feulgen’s stain to visualize bell shaped nuclei  (red 
arrows) characteristic of metakaryotic cells.  Histopathological slides of each section were 
scanned at x20 objective light microcopy to localize and count metakaryotic cells. Metakaryotic 
nuclei in fibrotic part of skin biopsy of healthy control were detected at very low frequency ~ 
1x10-5. In ‘upper’ section of biopsies, mostly presented by epithelial tissues and little of collagen 
deposition, the frequency of metakaryotic cells was higher in affected SSc biopsies, ~1 x10-3. In 
contrast,  the middle and lower sections of SSc biopsies characterized by extensive thickness of 
collagen fibrils, the fraction of metakaryotic cells reaches ~31 x10-3. (B) Examples of 
metakaryotic cells (bell shaped nuclei, arrowed) amitotic divisions (symmetrical, left panel; 
asymmetrical, right panel) as seen in fibrotic parts of SSc with extensive deposition of collagen.  
(C) Abnormal blood  vessels with multiple bleb like structures consistent with endothelial cell 
apoptosis.  ~90%  of 10-20um and 30-60 um diameter blood vessels were abnormal /dying in 
affected SSc and ~50-70% in unaffected skin biopsies.  No abnormal blood vessels were observed 
in healthy controls.  (D) Normal looking small (~ 10 um) blood vessels in affected and unaffected 
SSc skin  with ‘attached’ metakaryotic stem cells (arrowed) are probably  ‘de novo’ angiogenesis, 
blood vessels regeneration. (E) Furthermore, osteoclasts (arrows) were seen in parts with 
‘damaged’ blood vessels (left panel) as well as in thick collagenous parts (right panel) only in  




Figure 2 Effect of scleroderma disease lesional blister fluid and microenvironment cytokine IL-
31 on gene expression by MSCs.  (A) SSc blister fluid or control BF each diluted 1:125 in DMEM 
or recombinant IL-31 (50ng/ml) were added to MSCs in standard tissue culture media and gene 
expression profiled by Ilumina NGS after 16 hours.  Hierarchial clustering indicated clear 
separation of the 2 cell types; 1-16 representing MSC samples and 33-48 healthy dermal 
fibroblast. Distinct patterns of gene expression leading to hierarchial clustering of candidate 
factors were consistently induced in MSCs but not fibroblasts by SSc BF.  (B) Significantly 
increased gene expression was seen in factors relevant to myofibroblast differentiation, ACTA2, 
COL1 and CTGF. Furthermore, there was loss of stem cell marker NT5E and growth arrest gene 
GAS1. Changes in gene expression were generally greater in magnitude with SSc BF versus control 
BF, and in general not recapitulated by IL-31 (50 ng/ml) treatment, although as shown in (C) high 
levels of IL-31 were present in the BF. (D) IPA predicted activation of signalling pathways including 









Figure 3 Phenotypic changes induced in MSCs by scleroderma blister fluid: role of TGFβ (A) qPCR 
analysis of MSCs indicated that SSc BF, even when diluted 1;125 induced αSMA, more than 
control samples, consistent with myofibroblast commitment. (B) MSCs were treated with serum 
free media, TGFβ (4 ng/ml), SSc and healthy control blister fluid (BF) (1:125) with or without 1D11 
(10 g/ml), Wortmannin (100 nM) and/or U0126 (5 M). SSc blister fluid significantly induced 
more -SMA expression compared to serum free media (p=0.0004) and healthy control blister 
fluid (p=0.048), an effect which was fully inhibited by the TGFβ antibody 1D11. Signalling pathway 
inhibitors Wortmannin and U0126, also fully reversed SSc blister fluid (both p<0.0001). (C)  Levels 
of TGFβ1 in SSc and control BF. (D) Scratch wound assays SSc BF and the cytokine IL-31 induced 
migration equivalent to 10% serum positive control. By 24 hours 10% positive control had 
induced migration p=0.03 vs 0.2% serum.  Also SSc BF induced migration more than 0.2% serum 
controls, p=0.016. Furthermore, the addition of Wortmannin inhibited migration induced by IL-
31, p= 0.027 IL31 vs IL31+W.  (E) MSC populated gel contraction at 24 hours indicated that SSc BF 
enhanced contractility  measured by loss of gel weight (g) (p=0.002), similar to 10% serum as 
positive control (p=0.0062). IL-31 and control blister fluid (cBF) by comparison, did not result in 
significant gel weight loss. (F) Oil red O assay at 10 days confirmed suppression of adipogenesis 
by SSc blister fluid (but P NS). (G,H) Western blotting was used to demonstrate myofibroblast-
like commitment of MSCs following treatment with SSc BF more than control BF and antagonised 
by the TGFβ signalling inhibitor SB431542. N=3 replicates for each experiments.  *=p<0.05, 
**=p<0.01, ***=p<0.001, ****=p<0.0001 determined by one-way ANOVA with Tukey’s Post Hoc 
test for multiple comparisons. AM=adipogenic media, HC=healthy control,  SSc=scleroderma 
BF=blister fluid.  
 
Figure 4 Role of mechanical stress in MSC commitment in SSc  Modelling the tissue stiffness, 
soft 4 kPa or stiff 50kPa gels were used as ECM susbtrates for cultures of MSCs maintained with 
or without SSc BF  or TGFβ.  (A) Effect of SSc BF with or without the CCG mechanosensing 
inhibitor, on soft or stiff matrices on αSMA and CTGF by qPCR.  (B) Effect of tissue stiffness on 
TGFβ (4 ng/ml) induction of on αSMA and CTGF in MSCs.  Both α-SM and CTGF were suppressed 
by CCG1423 (10µM), indicating dependence on MRTF-A signal transduction. (C) MSCs cultured 
under osteogenic conditions on soft and stiff gels, effect of adding TGFβ or IL-31 and showing the 
effect of CCG1423 on osteogenic differentiation. (OIM=osteogenesis inducing medium, 
*=p<0.05, **=p<0.01, ***=p<0.001, ****=p<0.0001). 
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